Longeveron INC Form 4 insider transactions

Nirav S. Jhaveri, Chief Financial Officer of Longeveron Inc., reported a transaction in 742 shares of common stock on October 1, 2026.

Stephen H Willard, Chief Executive Officer of Longeveron Inc., reported a transaction in 1,987 shares of common stock on October 1, 2026.

Nataliya Agafonova, Chief Medical Officer of Longeveron Inc., reported a transaction in 2,913 shares of common stock on October 1, 2026.

Paul T Lehr, General Counsel, Secretary of Longeveron Inc., reported a transaction in 2,253 shares of common stock on October 1, 2026.

Devin Blass, CTO & SVP of CMC of Longeveron Inc., reported a transaction in 2,520 shares of common stock on October 1, 2026.

Nirav S. Jhaveri, Chief Financial Officer of Longeveron Inc., received 300,000 shares of common stock on August 17, 2026.

Paul T Lehr, General Counsel, Secretary of Longeveron Inc., received 286,000 shares of common stock on August 19, 2026.

Roger Joseph Hajjar, a Director of Longeveron Inc., received 36,000 shares of common stock on August 19, 2026.

Rock Soffer, a Director of Longeveron Inc., received 36,000 shares of common stock on August 19, 2026.

George A. Paletta Jr., a Director of Longeveron Inc., received 36,000 shares of common stock on August 19, 2026.

Leah Rush Cann, a Director of Longeveron Inc., received 36,000 shares of common stock on August 19, 2026.

Ursula Ungaro, a Director of Longeveron Inc., received 36,000 shares of common stock on August 19, 2026.

Arjun Jj Desai, a Director of Longeveron Inc., received 36,000 shares of common stock on August 19, 2026.

Devin Blass, CTO & SVP of CMC of Longeveron Inc., received 286,000 shares of common stock on August 19, 2026.

Nataliya Agafonova, Chief Medical Officer of Longeveron Inc., received 286,000 shares of common stock on August 19, 2026.

Deborah Ascheim, a Director of Longeveron Inc., received 36,000 shares of common stock on August 19, 2026.

Joshua Hare, Chief Scientific Officer, a Director and 10% owner of Longeveron Inc., received 286,000 shares of common stock on August 19, 2026.

Longeveron Inc. reports a significant stock transaction by Chief Scientific Officer Joshua Hare, involving restricted stock units and stock options.

Longeveron Inc. CEO Stephen H. Willard reported a disposition of 18,046 shares of Class A Common Stock to cover tax obligations related to vested restricted stock units.

Longeveron Inc. CFO Lisa Locklear reports a transaction involving the withholding of shares for tax obligations and holds a significant number of restricted stock units.

Longeveron Inc. Chief Medical Officer Nataliya Agafonova reported a transaction involving the sale of 22,505 shares of Class A Common Stock to cover tax obligations related to a restricted stock unit award.

Longeveron Inc. CTO Devin Blass reported a transaction involving the sale of company stock to cover tax obligations related to vested restricted stock units.

Longeveron Inc. reports that General Counsel Paul T. Lehr sold 13,143 shares of Class A Common Stock to cover tax obligations related to RSU vesting.

Longeveron Inc. General Counsel and Secretary Paul T. Lehr was granted 250,000 time-based restricted stock units.

Longeveron Inc. CEO Stephen H. Willard was granted 500,000 time-based restricted stock units as part of an equity incentive.

Longeveron Inc. CTO and SVP of CMC Devin Blass was awarded 250,000 time-based restricted stock units.

Longeveron Inc. Chief Medical Officer Nataliya Agafonova was granted 250,000 restricted stock units as part of an equity incentive.

Longeveron Inc. CFO Lisa Locklear was granted 250,000 time-based restricted stock units as part of an equity compensation award.

Longeveron Inc. reports a stock transaction by General Counsel and Secretary Paul T. Lehr, involving the withholding of shares for tax obligations.

Longeveron Inc. Chief Medical Officer Nataliya Agafonova reported a transaction involving the sale of shares to cover tax obligations related to restricted stock unit vesting.